These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 20409441)
61. Pharmacotherapies and personalized medicine for alcohol use disorder: a review. Lohoff FW Pharmacogenomics; 2020 Oct; 21(15):1117-1138. PubMed ID: 32807012 [TBL] [Abstract][Full Text] [Related]
62. The Smoking Cessation and Reduction in Pregnancy Treatment (SCRIPT) Adoption Scale: evaluating the diffusion of a tobacco treatment innovation to a statewide prenatal care program and providers. Windsor R; Cleary S; Ramiah K; Clark J; Abroms L; Davis A J Health Commun; 2013; 18(10):1201-20. PubMed ID: 23799823 [TBL] [Abstract][Full Text] [Related]
63. Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. Knudsen HK; Roman PM; Oser CB J Addict Med; 2010 Jun; 4(2):99-107. PubMed ID: 20835350 [TBL] [Abstract][Full Text] [Related]
64. Predischarge Injectable Versus Oral Naltrexone to Improve Postdischarge Treatment Engagement Among Hospitalized Veterans with Alcohol Use Disorder: A Randomized Pilot Proof-of-Concept Study. Busch AC; Denduluri M; Glass J; Hetzel S; Gugnani SP; Gassman M; Krahn D; Deyo B; Brown R Alcohol Clin Exp Res; 2017 Jul; 41(7):1352-1360. PubMed ID: 28605827 [TBL] [Abstract][Full Text] [Related]
65. A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers? Roberts W; Verplaetse TL; Ramchandani VA; McKee SA Alcohol Clin Exp Res; 2021 Jan; 45(1):15-24. PubMed ID: 33190310 [TBL] [Abstract][Full Text] [Related]
66. Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use. Alanis-Hirsch K; Croff R; Ford JH; Johnson K; Chalk M; Schmidt L; McCarty D J Subst Abuse Treat; 2016 Mar; 62():68-73. PubMed ID: 26654934 [TBL] [Abstract][Full Text] [Related]
67. The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study. Knudsen HK; Roman PM J Subst Abuse Treat; 2016 Mar; 62():62-7. PubMed ID: 26689318 [TBL] [Abstract][Full Text] [Related]
68. Physicians' opinions about medications to treat alcoholism. Mark TL; Kranzler HR; Song X; Bransberger P; Poole VH; Crosse S Addiction; 2003 May; 98(5):617-26. PubMed ID: 12751979 [TBL] [Abstract][Full Text] [Related]
69. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Hersh D; Van Kirk JR; Kranzler HR Psychopharmacology (Berl); 1998 Sep; 139(1-2):44-52. PubMed ID: 9768541 [TBL] [Abstract][Full Text] [Related]
70. Medicaid coverage of medications to treat alcohol and opioid dependence. Mark TL; Lubran R; McCance-Katz EF; Chalk M; Richardson J J Subst Abuse Treat; 2015 Aug; 55():1-5. PubMed ID: 25921475 [TBL] [Abstract][Full Text] [Related]
71. The Prescription of Anticraving Medication and its Economic Consequences. Holzbach R; Stammen G; Kirchhof U; Scherbaum N Eur Addict Res; 2019; 25(5):224-228. PubMed ID: 31216535 [TBL] [Abstract][Full Text] [Related]
72. A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri. Crits-Christoph P; Markell HM; Gibbons MB; Gallop R; Lundy C; Stringer M; Gastfriend DR J Subst Abuse Treat; 2016 Nov; 70():50-57. PubMed ID: 27692188 [TBL] [Abstract][Full Text] [Related]
73. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients. Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J Addiction; 2021 Aug; 116(8):1990-1998. PubMed ID: 33394527 [TBL] [Abstract][Full Text] [Related]
74. National trends in alcohol pharmacotherapy: Findings from an Australian claims database. Morley KC; Logge W; Pearson SA; Baillie A; Haber PS Drug Alcohol Depend; 2016 Sep; 166():254-7. PubMed ID: 27394934 [TBL] [Abstract][Full Text] [Related]
75. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Morley KC; Teesson M; Reid SC; Sannibale C; Thomson C; Phung N; Weltman M; Bell JR; Richardson K; Haber PS Addiction; 2006 Oct; 101(10):1451-62. PubMed ID: 16968347 [TBL] [Abstract][Full Text] [Related]
76. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices. Andraka-Christou B; Capone MJ Int J Drug Policy; 2018 Apr; 54():9-17. PubMed ID: 29324253 [TBL] [Abstract][Full Text] [Related]
77. Mapping the Diffusion of Technology in Orthopaedic Surgery: Understanding the Spread of Arthroscopic Rotator Cuff Repair in the United States. Austin DC; Torchia MT; Lurie JD; Jevsevar DS; Bell JE Clin Orthop Relat Res; 2019 Nov; 477(11):2399-2410. PubMed ID: 31393337 [TBL] [Abstract][Full Text] [Related]
78. Factors influencing the adoption of an innovation: an examination of the uptake of the Canadian Heart Health Kit (HHK). Scott SD; Plotnikoff RC; Karunamuni N; Bize R; Rodgers W Implement Sci; 2008 Oct; 3():41. PubMed ID: 18831766 [TBL] [Abstract][Full Text] [Related]
79. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study. Mann K; Kiefer F; Smolka M; Gann H; Wellek S; Heinz A; Alcohol Clin Exp Res; 2009 Apr; 33(4):674-83. PubMed ID: 19170666 [TBL] [Abstract][Full Text] [Related]